BQPrime
•69% Informative
HDFC Securities Retail Research Valuation and Recommendation: Astrazeneca Pharma India Ltd. has strong portfolio of products that caters mainly to super-specialists and specialist doctors.
Strong cash rich balance sheet enables it to look out for acquisition, in-licensing opportunities.
We expect 14.5% compound annual growth rate in sales and 27%/45% CAGR in Ebita /profit after tax over FY23-25E.
VR Score
74
Informative language
81
Neutral language
27
Article tone
formal
Language
English
Language complexity
61
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links